Please login to the form below
HER2 inhibitor
This page shows the latest HER2 inhibitor news and features for those working in and with pharma, biotech and healthcare.
Strong five-year survival data for Kisqali in breast cancer
Novartis’ Kisqali plus letrozole offers more than a year survival benefit for postmenopausal women with HR+/HER2 advanced breast cancer. ... Kisqali is approved in the US and EU as initial endocrine-based therapy in combination with an aromatase
Latest news
-
UK approval for Seagen’s oral HER2 inhibitor Tukysa
metastatic breast cancer who have previously received at least two anti-HER2 treatment regimens. ... The oral HER2 inhibitor is also approved in the US for the treatment of HER2-positive advanced cancer.
-
Seattle Genetics wins FDA priority review for oral HER2 drug
If approved will compete with AZ/Daiichi Sankyo's Enhertu. Seattle Genetics has scored a US Food and Drug Administration (FDA) priority review for its oral HER2 inhibitor tucatinib in breast ... If Seattle does gain approval for tucatinib, it will go on
-
AZ, Daiichi Sankyo get early okay for DS-8201, now named Enhertu
The US regulator has cleared the HER2 inhibitor drug – now known as Enhertu (trastuzumab deruxtecan) – for metastatic HER2-positive disease in patients who have previously been treated with two or more ... s chemotherapy Xeloda (capecitabine) in
-
AZ, Daiichi Sankyo strengthen case for HER2 candidate
Its nearest rival in the area is Roche’s anti-HER2 ADC Kadcyla (trastuzumab emtansine). ... Also looking to encroach on the HER2 market is Seattle Genetics, with its orally-active HER2 inhibitor tucatinib.
-
Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day
It’s due for first regulatory verdicts in 2021. Pevonedistat (TAK-924) for HR-MDS: Pevonedistat is a selective NEDD8 activating enzyme (NAE) inhibitor being developed as a cancer treatment, initially ... TAK-788 for non-small cell lung cancer:Phase 1/2
More from news
Approximately 2 fully matching, plus 18 partially matching documents found.
Latest Intelligence
-
Deal Watch January 2018
Acquisition company. 628. Cascadian Therapeutics/Seattle Genetics. Lead programme tucatinib, oral, small molecule TKI highly selective for HER2 (p2). ... This acquisition brings tucatinib, an oral tyrosine kinase inhibitor that is highly selective for
-
Deal Watch table for December 2014
440. OncoEthix / Merck &Co. Lead product oral BET inhibitor, OTX015 for oncology indications (p1b). ... ONT-380 (ARRY-380), oral, reversible and selective small molecule HER2 inhibitor (p1).
-
Pharma deals during April 2014
GSK's recently approved MEK inhibitor Mekinist and BRAF inhibitor Tafinlar will position Novartis to become a leader in the potential blockbuster market for metastatic melanoma, neglected by their current portfolio. ... Additional GSK products include
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- bluebird bio reveals plans to launch two gene therapies
- AstraZeneca and MSD’s breast cancer drug Lynparza receives EC approval
- Eli Lilly to make bebtelovimab commercially available to US states from August
- Regeneron terminates four clinical trials of its COVID-19 antibody cocktail REGEN-COV
- The patient voice – the value of patient-reported outcomes in HTA
- Biogen and Eisai share latest lecanemab results for the treatment of Alzheimer's disease
- Strategic commitment
- Pfizer set to acquire Global Blood Therapeutics in deal worth $5.4bn
- AstraZeneca and Daiichi Sankyo get FDA approval for breast cancer drug
- NHS England launches hepatitis C screening scheme to reach 2030 elimination goal
- Bayer’s Nubeqa receives FDA approval to treat metastatic prostate cancer
- Valneva and Pfizer initiate phase 3 Lyme disease vaccine study
- GSK’s ViiV and Medicines Patent Pool agree deal for HIV prevention
- GSK/Merck KGgA cancer drug fails in third trial
- Chiesi Group's Trimbow wins European licence
- Roche shares new positive Ocrevus data for MS patients
- Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection
- Using behavioural psychology to improve patient recruitment
PMHub
Health Unlimited
Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...
Latest intelligence
- Strategic commitment
- ...
- KOL Ambassador Program & Podcast Creation: A Customer Story
- ...
- Animation: Living With
- The journey from the patient's perspective...
